Longport signs $5 million R&D deal
Ultrasound developer Longport of Swarthmore, PA, last month signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longport’s R&D efforts. The funds will be used to expand the
Ultrasound developer Longport of Swarthmore, PA, last month signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longports R&D efforts. The funds will be used to expand the companys list of applications for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). Healthlink has also purchased an equity interest in Longport, according to the company.
Longport applied for 510(k) clearance for LDS in January, and hopes to receive clearance this month. The companys application to the Food and Drug Administration covers the use of LDS for dermatological indications, but Longport plans to research other indications, including podiatric, physical therapy, dental, burn treatment, and such oncologic applications as breast and cervical cancer.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
